# TerrAscend Corp.: overview

TSNDF · OTC · CIK 1778129 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tsndf.md) · [Financials](/companies/tsndf/financials.md) · [Filings](/companies/tsndf/filings.md) · [Insiders](/companies/tsndf/insiders.md)

Latest reported revenue: [$67.1m](/filings/0001193125-26-337940.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-337940).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [65.2](/filings/0001193125-25-268099.md) | [66.4 d](/filings/0001193125-26-104092.md) | [64.3](/filings/0001193125-26-210366.md) | [65.0](/filings/0001193125-26-337940.md) | [65.1](/filings/0001193125-25-268099.md) | [66.1 d](/filings/0001193125-26-104092.md) | [65.5](/filings/0001193125-26-210366.md) | [67.1](/filings/0001193125-26-337940.md) |
| Gross margin | % | [51.0%](/filings/0001193125-25-268099.md) | [52.9% d](/filings/0001193125-26-104092.md) | [53.9%](/filings/0001193125-26-210366.md) | [51.1%](/filings/0001193125-26-337940.md) | [52.1%](/filings/0001193125-25-268099.md) | [52.1% d](/filings/0001193125-26-104092.md) | [52.8%](/filings/0001193125-26-210366.md) | [54.0%](/filings/0001193125-26-337940.md) |
| Operating margin | % | [11.1%](/filings/0001193125-25-268099.md) | [17.6% d](/filings/0001193125-26-104092.md) | [19.0%](/filings/0001193125-26-210366.md) | [16.9%](/filings/0001193125-26-337940.md) | [17.1%](/filings/0001193125-25-268099.md) | [11.6% d](/filings/0001193125-26-104092.md) | [17.6%](/filings/0001193125-26-210366.md) | [18.0%](/filings/0001193125-26-337940.md) |
| Net margin | % | [(32.9%)](/filings/0001193125-25-268099.md) | [(45.4%) d](/filings/0001193125-26-104092.md) | [(19.1%)](/filings/0001193125-26-337940.md) | [(74.0%)](/filings/0001193125-26-337940.md) | [(37.7%)](/filings/0001193125-25-268099.md) | [5.4% d](/filings/0001193125-26-104092.md) | [(12.2%)](/filings/0001193125-26-337940.md) | [(12.0%)](/filings/0001193125-26-337940.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001193125-25-268099.md) | not reported | [(0.05)](/filings/0001193125-26-210366.md) | [(0.17)](/filings/0001193125-26-337940.md) | [(0.08)](/filings/0001193125-25-268099.md) | not reported | [(0.03)](/filings/0001193125-26-210366.md) | [(0.03)](/filings/0001193125-26-337940.md) |
| Free cash flow | $m | [2.0 d](/filings/0001193125-25-268099.md) | [7.0 d](/filings/0001193125-26-104092.md) | [5.6](/filings/0001193125-26-210366.md) | [0.5 d](/filings/0001193125-26-337940.md) | [0.4 d](/filings/0001193125-25-268099.md) | [6.3 d](/filings/0001193125-26-104092.md) | [7.6](/filings/0001193125-26-210366.md) | [4.9 d](/filings/0001193125-26-337940.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [194](/filings/0000950170-24-031450.md) | [248](/filings/0000950170-25-034600.md) | [251](/filings/0001193125-26-104092.md) | [268](/filings/0001193125-26-104092.md) | [261](/filings/0001193125-26-104092.md) |
| Gross margin | % | [57.9%](/filings/0000950170-24-031450.md) | [41.0%](/filings/0000950170-25-034600.md) | [55.1%](/filings/0001193125-26-104092.md) | [50.7%](/filings/0001193125-26-104092.md) | [52.3%](/filings/0001193125-26-104092.md) |
| Operating margin | % | [11.8%](/filings/0000950170-24-031450.md) | [(135.5%)](/filings/0000950170-25-034600.md) | [11.9%](/filings/0001193125-26-104092.md) | [14.5%](/filings/0001193125-26-104092.md) | [16.1%](/filings/0001193125-26-104092.md) |
| Net margin | % | [3.2%](/filings/0000950170-24-031450.md) | [(131.3%)](/filings/0000950170-25-034600.md) | [(34.6%)](/filings/0001193125-26-104092.md) | [(27.1%)](/filings/0001193125-26-104092.md) | [(31.2%)](/filings/0001193125-26-104092.md) |
| Diluted EPS | $ per share | [0.01](/filings/0000950170-24-031450.md) | [(1.35)](/filings/0000950170-25-034600.md) | [(0.34)](/filings/0001193125-26-104092.md) | [(0.28)](/filings/0001193125-26-104092.md) | [(0.29)](/filings/0001193125-26-104092.md) |
| Free cash flow | $m | [(71.7)](/filings/0000950170-24-031450.md) | [(65.8)](/filings/0000950170-25-034600.md) | [22.6](/filings/0001193125-26-104092.md) | [31.1](/filings/0001193125-26-104092.md) | [12.9](/filings/0001193125-26-104092.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tsndf/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Sterling Capital Management LLC](/funds/1329883.md) | 2026-06-30 | $54 | 80 |  | New +80 |

## Recent filings

[All 282 filings](/companies/tsndf/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-25 | 18:44 ET | [8-K](/filings/0001193125-26-363877.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-363877 |
| 2026-08-06 | 16:15 ET | [8-K](/filings/0001193125-26-338059.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-338059 |
| 2026-08-06 | 16:04 ET | [10-Q](/filings/0001193125-26-337940.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337940 |
| 2026-07-06 | 09:14 ET | [DEF 14A](/filings/0001193125-26-295591.md) | Proxy statement, period 2026-08-24 | 0001193125-26-295591 |
| 2026-06-29 | 17:05 ET | [8-K](/filings/0001193125-26-288696.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-288696 |
| 2026-06-25 | 16:58 ET | [8-K](/filings/0001193125-26-282981.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-282981 |
| 2026-06-15 | 17:04 ET | [8-K](/filings/0001193125-26-271256.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-271256 |
| 2026-05-07 | 07:45 ET | [8-K](/filings/0001193125-26-210379.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210379 |
| 2026-05-07 | 07:35 ET | [10-Q](/filings/0001193125-26-210366.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210366 |
| 2026-04-27 | 08:45 ET | [8-K](/filings/0001193125-26-179245.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-179245 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104092.md), filed Mar 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/eb31fc0b-2a48-4d76-b8f1-b7c90d895e49)

## About the filer

- CIK: 1778129
- Tickers: TSNDF
- Exchange: OTC
- SIC code: 100 Agricultural Production-Crops
- State of incorporation: A6
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.
